ARTICLES BY THIS AUTHOR
- 1/6/2020
Lannett launches 2 generics
Venlafaxine ER tablets, 150 mg and 225 mg, and lidocaine topical solution 4% had a market value of roughly $150 million and $17 million, respectively, for the 12 months ended November 2019. - 1/6/2020
Allergan reaches $300M settlement in Loestrin, Minastrin suit
Warner Chilcott and Watson subsidiaries will pay approximately $300 million under settlement agreements. - 1/3/2020
Daiichi Sankyo obtains FDA approval for Enhertu
Daiichi Sankyo's Enhertu provides a new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies. - 1/3/2020
Publix Pharmacy fills 100 millionth free prescription
Publix Pharmacy recently filled its 100 millionth free prescription as part of its free medication program. - 1/3/2020
Novadoz gets FDA nod for generic Uloric
The Febuxostat brand had a market value of over $430 million over the previous 12 months. - 1/3/2020
Adamas settles patent litigation dispute with Sandoz
Sandoz will be allowed to launch a generic version of Gocovri on March 4, 2030 or earlier under certain circumstances. - 1/2/2020
Allergan gets FDA OK for Ubrelvy
Ubrelvy is the first and only oral calcitonin gene-related peptide receptor antagonist for the treatment of migraine attacks once they start. - 1/2/2020
Lannett gets FDA nod for generic butalbital, acetaminophen and caffeine capsules
The two dosage strengths of BAC capsules have a combined estimated market value of approximately $68.6 million for the 12 months ended October 2019. - 1/2/2020
Dr. Reddy's intros generic Nitropress
The Nitropress brand and generics had a market value of approximately $8 million for the most recent 12 months ended October 2019. - 1/2/2020
Micro Labs, Mylan get FDA OK for generic Eliquis
The generic is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.